The prospective, open-label, multicenter Phase 3 ENDEAVOR trial included 929 patients with relapsed/refractory multiple myeloma from 27 countries in North America, South America, Europe and the Asia-Pacific region. See the study listed in Clinicaltrials.gov.  Amgen was the commercial sponsor having acquired the treatment (Kyprolis) from Onyx Pharmaceuticals. 

As reported in Healio, researchers have concluded in a Phase 3 trial that the combination of carfilzomib (Kyprolis, Amgen) and dexamethasone extended PFS and OS compared with bortezomib (Takeda Pharmaceuticals) and dexamethasone among patients with relapsed or refractory multiple myeloma regardless of baseline renal function base on post-hoc exploratory subgroup analysis. Meletios Dimopoulos, MD noted “the present analysis is the first head to head comparison of carfilzomib (Kyprolis, Amgen) and dexamethasone vs. bortezomib (Velcade, Takeda) and dexamethasone with regard to renal response and survival outcomes in patients with multiple myeloma with renal impairment.”

See the Healio article for further details or the results.

Source: Healio

Pin It on Pinterest